Recursion Pharmaceuticals Inc. logo

Recursion Pharmaceuticals Inc.

RXRX | NASDAQ
Chart Builder DCF Calculator
$3.97
+$0.14 (+3.66%)
At close: Sep 21, 2026, 4:00 PM ET
$3.98
+$0.01 (+0.26%)
Pre-market: Sep 22, 2026, 9:24 AM ET

Market Data

Market Cap
$2.08B
Enterprise Value
$1.6B
Beta
1.07
Average Volume
19.05M
Shares Outstanding (Diluted)
532.46M
Shares Change YoY
27.58%
Institutional Ownership
63.51%
Exchange
NASDAQ
ISIN
US75629V1044

Price Performance

Price Change 1M
16.1%
Price Change 3M
25.6%
Price Change 6M
25.2%
Price Change YTD
-5.5%
Price Change 1Y
-20.3%
Price Change 3Y
-49.9%
Price Change 5Y
-83.8%
1M CAGR (ann.)
23.3%
1Y CAGR (ann.)
-19.5%
5Y CAGR (ann.)
-31.4%
All-Time CAGR
-24.3%

Valuation

PE Ratio
-3.82
Forward PE
N/A
PEG Ratio
-0.07
Forward PEG
10.61
PS Ratio
37.97
Forward PS
35.50
PB Ratio
2.28
P/FCF Ratio
-4.80
P/Adj. FCF Ratio
-3.81
P/OCF Ratio
-6.02
EV/Sales
29.15
EV/EBIT
-3.06
EV/EBITDA
-3.60
EV/FCF
-3.69
Earnings Yield
-26.2%
FCF Yield
-20.8%
Adj. FCF Yield
-26.2%

Financial Health

Net Cash
$545.68M
Total Debt
$61.89M
Cash & Short-Term Investments
$545.68M
Total Assets
$1.21B
Current Ratio
5.03
Quick Ratio
5.03
Debt / Equity Ratio
0.07
Debt / EBITDA
-0.14
Debt / FCF
-0.14
OCF / Debt
-6.97
Interest Coverage
-364.62
Altman Z-Score
0.62
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
-46.7%
Operating Profit Margin
-991.7%
EBITDA Margin
-810.2%
Net Profit Margin
-945.9%
FCF Margin
-790.5%
Adj. FCF Margin
-996.4%
SBC / Revenue
165.4%
SBC Impact (per share)
-26.0%

Returns

Return on Assets
-42.8%
Return on Equity
-50.4%
Return on Invested Capital
-48.3%
Return on Capital Employed
-49.8%
Return on Tangible Assets
-67.4%

Historical Growth (CAGR)

Revenue CAGR 3Y
3.2%
Revenue CAGR 5Y
45.5%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
19.6%
EPS CAGR 5Y
1.6%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-11.3%
FCF CAGR 5Y
-24.8%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Hold
Analyst Count
10
EPS Growth Next 3Y
3.2%
Revenue Growth Next 3Y
65.2%
Earnings Date
Nov 3, 2026
EPS Estimate (next Q)
-$0.24
EPS Growth Est (next Q)
-33.3%
Revenue Est (next Q)
$14.16M
Revenue Growth Est (next Q)
173.6%

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$5.30
Price Target Upside
33.5%

Cash Flow

Operating Cash Flow
$-431.58M
Free Cash Flow
$-433.63M
Adj. Free Cash Flow
$-546.56M
FCF Per Share
-$0.67
OCF Per Share
-$0.66
OCF/S Ratio
-638.9%

Income Statement

Revenue
$54.86M
Gross Profit
$-25.6M
Operating Income
$-544.01M
EBITDA
$-444.45M
Net Income
$-518.89M
EPS (Diluted)
-$1.04
Revenue / Employee
$91.43K
Profit / Employee
$-864.81K
Employees
600

© 2026 bestshares.com. All rights reserved.